Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Humbrecht

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Transfusion Clinique Et Biologique : Journal De La Societe Francaise De Transfusion Sanguine|July 25, 2018
Platelet transfusion: Current challengesC Humbrecht, D Kientz, C Gachet
Transfusion Clinique Et Biologique : Journal De La Societe Francaise De Transfusion Sanguine|July 21, 2018
[Adaptation of platelet concentrates delivery to HAS/ANSM requirements evolution in EFS Grand-Est]D Kientz, C Humbrecht, H Isola, et al.
Transfusion Clinique Et Biologique : Journal De La Societe Francaise De Transfusion Sanguine|August 5, 2018
[Comparative study on platelet transfusion in Lorraine-Champagne and Alsace in 2015]C Humbrecht, S Somme, P Renaudier, et al.
La Revue De Medecine Interne|April 5, 2008
[Muscle lymphoma: a case report]S Robaday, F Héron, N Girszyn, et al.
Leukemia|June 30, 2012
Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AMLS Ettou, E Audureau, C Humbrecht, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2014
ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trialN Mounier, P Brice, S Bologna, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Transfusion Clinique Et Biologique : Journal De La Societe Francaise De Transfusion Sanguine|July 25, 2018
Platelet transfusion: Current challengesC Humbrecht, D Kientz, C Gachet
Transfusion Clinique Et Biologique : Journal De La Societe Francaise De Transfusion Sanguine|July 21, 2018
[Adaptation of platelet concentrates delivery to HAS/ANSM requirements evolution in EFS Grand-Est]D Kientz, C Humbrecht, H Isola, et al.
Transfusion Clinique Et Biologique : Journal De La Societe Francaise De Transfusion Sanguine|August 5, 2018
[Comparative study on platelet transfusion in Lorraine-Champagne and Alsace in 2015]C Humbrecht, S Somme, P Renaudier, et al.
La Revue De Medecine Interne|April 5, 2008
[Muscle lymphoma: a case report]S Robaday, F Héron, N Girszyn, et al.
Leukemia|June 30, 2012
Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AMLS Ettou, E Audureau, C Humbrecht, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2014
ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trialN Mounier, P Brice, S Bologna, et al.
Pageof 1